IVI Appoints Dr. Richard Chapman as Chief Scientific Officer

IVI Appoints Dr. Richard Chapman as Chief Scientific Officer TrialsiteN

The Innovation and Value Initiative (IVI) – a nonprofit organization dedicated to advancing the science, practice, and use of value assessment in healthcare – today announced that Rick Chapman, PhD, will be its next Chief Scientific Officer. Chapman, who is currently Director of Health Economics at the Institute for Clinical and Economic Review (ICER), will start March 1.

“As value assessment plays an increasingly important role in healthcare – and as the number of assessment organizations grows – we’re thrilled Rick is joining the IVI team,” said Jennifer Bright, IVI’s Executive Director. “His wealth of health economics and outcomes research experience will guide IVI’s contributions to research and methods that ensure patient-centricity, transparency, and flexibility in economic modeling and value assessment.”   

At ICER, Chapman led the development of economic evaluations that accompanied rigorous reviews of clinical evidence, including the assessment of potential costs, cost-effectiveness, and budgetary impact of a wide range of diagnostic, prognostic, therapeutic, and other clinical interventions.

Sam Nussbaum, MD, IVI’s Board of Directors President and former Chief Medical Officer for Anthem, said: “As value assessment becomes an underpinning of U.S. health policy and decision-making, scientific testing and validation of models and methods become increasingly important. Rick’s expertise will be an important asset to the IVI Team and to healthcare decision-makers adopting value assessments into their processes.”

Prior to ICER, Chapman was a Vice President of Health Economics and Outcomes Research (HEOR) at Avalere Health, where he directed the design and analysis of economic evaluations and health outcomes studies. Chapman was also a principal in HEOR and U.S. regional lead for the Retrospective Database Analysis Center of Excellence at IMS Health. Previously, he was at the Center for Risk Analysis at the Harvard School of Public Health.

“I’m excited to join this expanding value assessment nonprofit at such a pivotal time,” Chapman said. “If value frameworks are to be used to enhance patients’ lives, improving the design of value assessments to better incorporate patient perspectives and lived experiences at the onset of model construction is paramount. I’m looking forward to helping IVI apply its patient-centric and transparent approach to additional disease-state models.”

Chapman holds a PhD in health policy with a concentration in decision sciences from Harvard University. He also holds an MS in health policy and management from the Harvard School of Public Health.